Thus, it is becoming well known that platinum-based agents can induce T cell responses that would be beneficial for cancer treatment; however, it is currently unknown where these CD8+ T cells will migrate from the spleen in response to oxaliplatin treatment and whether a subset of these cells are MAIT cells (requires tetramer which is unavailable to us) and this requires further work. This evidence concerns the gene CD8A and cancer.